Psilocybin edged past placebo in treatment-resistant depression
What they did
Compass Pathways ran a phase 3 trial of a single 25mg dose of its synthetic psilocybin across thirty-two US sites in people with treatment-resistant depression, measuring depression scores at six weeks.
What they found
The company reported the trial met its primary endpoint, with a 3.6 point advantage over placebo on the MADRS depression scale at week six.
Worth knowing
This is a corporate press release dated June 2025, not a published paper. It has not been peer reviewed and the full data have not been released. A 3.6 point MADRS difference is statistically clear and clinically modest. Treat it as news, not as evidence.
Compass Pathways. Phase 3 COMP005 trial results, company press release, June 2025.
Read the sourceKeep reading
depressionOnly the highest dose eased treatment-resistant depressiondepressionIn ordinary depression, psilocybin beat placebo by twelve pointsdepressionPsilocybin and a standard antidepressant, with no clear winnerEvery trial in this section used a single large dose, given in a clinic, with trained people in the room for the whole session. That is a different activity from anything sold on this site. More on why that distinction matters.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.